# US 2019/0375708 A1 · Hepatitis b capsid assembly modulators

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0375708 A1
- Document ID: US20190375708A1
- Status: Published application
- Kind: A1
- Application number: 16/438,361
- Filed: 2019-06-11
- Published: 2019-12-12
- Earliest claimed: 2018-06-11
- Assignees: Venatorx Pharmaceuticals, Inc.
- Applicants: VenatoRx Pharmaceuticals, Inc.
- Inventors: Christopher J. BURNS; Glen COBURN; Bin LIU; Jiangchao YAO; Christopher BENETATOS; Steven A. BOYD; Stephen M. CONDON; Thomas HAIMOWITZ
- Web page: https://patentgrep.com/patent/US20190375708A1

## CPC

- C07D 207/34: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- A61P 31/20: for DNA viruses
- C07D 207/337: Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D 401/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 401/14: containing three or more hetero rings
- C07D 403/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 403/12: linked by a chain containing hetero atoms as chain links
- C07D 405/12: linked by a chain containing hetero atoms as chain links
- C07D 405/14: containing three or more hetero rings
- C07D 409/12: linked by a chain containing hetero atoms as chain links
- C07D 409/14: containing three or more hetero rings
- C07D 413/12: linked by a chain containing hetero atoms as chain links
- C07D 413/14: containing three or more hetero rings
- C07D 417/12: linked by a chain containing hetero atoms as chain links
- C07D 471/04: Ortho-condensed systems
- C07D 487/04: Ortho-condensed systems
- C07D 498/04: Ortho-condensed systems
- C07D 513/04: Ortho-condensed systems
- C07F 5/025: {Boronic and borinic acid compounds}
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)

## Abstract

Described herein are hepatitis B capsid assembly modulators and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of hepatitis B.

## Claims

### Claim 1

A compound of Formula (I), or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof:
wherein:
Ring A is aryl, heteroaryl, cycloalkyl, or heterocycloalkyl;
each R11 is independently halogen, —CN, —OH, —ORa, —SH, —SRa, —S(═O)Ra, —S(═O)2Ra, —NO2, —NRbRc, —NHS(═O)2Ra, —S(═O)2NRbRc, —C(═O)Ra, —OC(═O)Ra, —C(═O)ORb, —OC(═O)ORb, —C(═O)NRbRc, —OC(═O)NRbRc, —NRbC(═O)NRbRc, —NRbC(═O)Ra, —NRbC(═O)ORb, C1-C6alkyl, C1-C6haloalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C2-C6alkenyl, C2-C6alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, —C1-C6alkyl(aryl), —C1-C6alkyl(heteroaryl), —C1-C6alkyl(cycloalkyl), or —C1-C6alkyl(heterocycloalkyl); wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R1;
or two R11 on adjacent atoms are taken together with the atoms to which they are attached to form a cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; each optionally substituted with one, two, or three R2;
R12 is hydrogen or C1-C6alkyl;
R13 is hydrogen, halogen, —CN, —OH, —ORa, —SH, —SRa, —S(═O)Ra, —S(═O)2Ra, —NO2, —NRbRc, —NHS(═O)2Ra, —S(═O)2NRbRc, —C(═O)Ra, —OC(═O)Ra, —C(═O)ORb, —OC(═O)ORb, —C(═O)NRbRc, —OC(═O)NRbRc, —NRbC(═O)NRbRc, —NRbC(═O)Ra, —NRbC(═O)ORb, C1-C6alkyl, C1-C6haloalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C2-C6alkenyl, C2-C6alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, —C1-C6alkyl(aryl), —C1-C6alkyl(heteroaryl), —C1-C6alkyl(cycloalkyl), or —C1-C6alkyl(heterocycloalkyl); wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R3;
R14 is hydrogen, halogen, —CN, —OH, —ORa, —SH, —SRa, —S(═O)Ra, —S(═O)2Ra, —NO2, —NRbRc, —NHS(═O)2Ra, —S(═O)2NRbRc, —C(═O)Ra, —OC(═O)Ra, —C(═O)ORb, —OC(═O)ORb,—C(═O)NRbRc, —OC(═O)NRbRc, —NRbC(═O)NRbRc, —NRbC(═O)Ra, —NRbC(═O)ORb, C1-C6alkyl, C1-C6haloalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C2-C6alkenyl, C2-C6alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, —C1-C6alkyl(aryl), —C1-C6alkyl(heteroaryl), —C1-C6alkyl(cycloalkyl), or —C1-C6alkyl(heterocycloalkyl); wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R4;
R15 is hydrogen, —S(═O)Ra, —S(═O)2Ra, —S(═O)2NRbRc, —C(═O)Ra, —C(═O)ORb, —C(═O)NRbRc, C1-C6alkyl, C1-C6haloalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C2-C6alkenyl, C2-C6alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, —C1-C6alkyl(aryl), —C1-C6alkyl(heteroaryl), —C1-C6alkyl(cycloalkyl), or —C1-C6alkyl(heterocycloalkyl); wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R5;
R16 is hydrogen, —CN, —OR20, C1-C6alkyl, C1-C6haloalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C2-C6alkenyl, C2-C6alkynyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, heteroaryl, —C1-C6alkyl(aryl), —C1-C6alkyl(heteroaryl), —C1-C6alkyl(cycloalkyl), or —C1-C6alkyl(heterocycloalkyl); wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R7;
R17 is C1-C6hydroxyalkyl, cycloalkyl, or heterocycloalkyl; each optionally substituted with one, two, or three R7;
each R20 is independently hydrogen, C1-C6alkyl, C1-C6haloalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C2-C6alkenyl, C2-C6alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R7;
n is 0-4;
each R1, R2, R3, R4, and R5 is independently oxo, halogen, —CN, —OH, —ORa, —SH, —SRa, —S(═O)Ra, —S(═O)2Ra, —NO2, —NRbRc, —NHS(═O)2Ra, —S(═O)2NRbRc, —C(═O)Ra, —OC(═O)Ra, —C(═O)ORb, —OC(═O)ORb, —C(═O)NRbRc, —OC(═O)NRbRc, —NRbC(═O)NRbRc, —NRbC(═O)Ra, —NRbC(═O)ORb, C1-C6alkyl, C1-C6haloalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C2-C6alkenyl, C2-C6alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, —C1-C6alkyl(aryl), —C1-C6alkyl(heteroaryl), —C1-C6alkyl(cycloalkyl), or —C1-C6alkyl(heterocycloalkyl); wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three oxo, halogen, —CN, —OH, —OMe, —S(═O)Me, —S(═O)2Me, —NH2, —S(═O)2NH2, —C(═O)Me, —C(═O)OH, —C(═O)OMe, C1-C6alkyl, C1-C6haloalkyl, C1-C6hydroxyalkyl, or C1-C6aminoalkyl;
each R7 is independently oxo, halogen, —CN, —OH, —ORa, —SH, —SRa, —S(═O)Ra, —S(═O)2Ra, —NO2, —NRbRc, —NHS(═O)2Ra, —S(═O)2NRbRc, —B(ORb)(ORc), —C(═O)Ra, —OC(═O)Ra, —C(═O)ORb, —OC(═O)ORb, —C(═O)NRbRc, —OC(═O)NRbRc, —NRbC(═O)NRbC, —NRbC(═O)Ra, —NRbC(═O)ORb, C1-C6alkyl, C1-C6haloalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C2-C6alkenyl, C2-C6alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, —C1-C6alkyl(aryl), —C1-C6alkyl(heteroaryl), —C1-C6alkyl(cycloalkyl), or —C1-C6alkyl(heterocycloalkyl); wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R7a;
each R7a is independently oxo, halogen, —CN, —OH, —ORa, —NRbRc, —C(═O)Ra, —C(═O)ORb, C(═O)NRbRc, C1-C6alkyl, C1-C6haloalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three oxo, halogen, —CN, —OH, —OMe, —S(═O)Me, —S(═O)2Me, —NH2, —S(═O)2NH2, —C(═O)Me, —C(═O)OH, —C(═O)OMe, C1-C6alkyl, C1-C6haloalkyl, C1-C6hydroxyalkyl, or C1-C6aminoalkyl;
each Ra is independently C1-C6alkyl, C1-C6haloalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C2-C6alkenyl, C2-C6alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three oxo, halogen, —CN, —OH, —OMe, —S(═O)Me, —S(═O)2Me, —NH2, —S(═O)2NH2, —C(═O)Me, —C(═O)OH, —C(═O)OMe, C1-C6alkyl, C1-C6haloalkyl, C1-C6hydroxyalkyl, or C1-C6aminoalkyl; and
each Rb and Rc are independently hydrogen, C1-C6alkyl, C1-C6haloalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C2-C6alkenyl, C2-C6alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three oxo, halogen, —CN, —OH, —OMe, —S(═O)Me, —S(═O)2Me, —NH2, —S(═O)2NH2, —C(═O)Me, —C(═O)OH, —C(═O)OMe, C1-C6alkyl, C1-C6haloalkyl, C1-C6hydroxyalkyl, or C1-C6aminoalkyl;
or Rb and Rc are taken together with the atom to which they are attached to form a heterocycloalkyl optionally substituted with one, two, or three oxo, halogen, —CN, —OH, —OMe, —S(═O)Me, —S(═O)2Me, —NH2, —S(═O)2NH2, —C(═O)Me, —C(═O)OH, —C(═O)OMe, C1-C6alkyl, C1-C6haloalkyl, C1-C6hydroxyalkyl, or C1-C6aminoalkyl.

### Claim 2 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
R14 is hydrogen or C1-C6alkyl.

### Claim 3 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
R15 is hydrogen, C1-C6alkyl, C1-C6haloalkyl, or C1-C6hydroxyalkyl.

### Claim 4 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
R15 is C1-C6alkyl.

### Claim 5 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
R12 is hydrogen or C1-C6alkyl.

### Claim 6 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
R13 is hydrogen or C1-C6alkyl.

### Claim 7 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
Ring A is aryl or heteroaryl.

### Claim 8 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
each R11 is independently halogen, —CN, C1-C6alkyl, or C1-C6haloalkyl.

### Claim 9 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
n is 0-3.

### Claim 10 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
R16 is hydrogen or C1-C6alkyl.

### Claim 11 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
R17 is C1-C6hydroxyalkyl or cycloalkyl; wherein alkyl and cycloalkyl is independently optionally substituted with one, two, or three R7.

### Claim 12

(canceled)

### Claim 13 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
R17 is cycloalkyl optionally substituted with one, two, or three R7.

### Claim 14 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
each R7 is independently oxo, halogen, —CN, —OH, —ORa, —S(═O)2Ra, —NRbRc, —NHS(═O)2Ra, —S(═O)2NRbRc, —B(ORb)(ORc), —C(═O)Ra, —C(═O)ORb, —C(═O)NRbRc, —NRbC(═O)Ra, C1-C6alkyl, C1-C6haloalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R7a.

### Claim 15 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
each R7 is independently halogen, —CN, —OH, —ORa, —NRbRc, —C(═O)ORb, —C(═O)NRbRc, C1-C6alkyl, C1-C6haloalkyl, C1-C6hydroxyalkyl, cycloalkyl, or heteroaryl; wherein each alkyl, cycloalkyl, and heteroaryl is independently optionally substituted with one, two, or three R7a.

### Claim 16 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
each R7a is independently halogen, —CN, —OH, —ORa, —NRbRc, C1-C6alkyl, or C1-C6haloalkyl.

### Claim 17 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, selected from the group consisting of:

### Claim 18 (depends on 1)

A pharmaceutical composition comprising a compound of claim 1, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, and a pharmaceutically acceptable excipient.

### Claim 19 (depends on 1)

A method of treating hepatitis B in a subject, comprising administering to the subject a compound of claim 1, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.

### Claim 20

(canceled)
